For the quarter, pharmaceutical sales were recorded at $13bn compared to $12.7bn in Q3 2021, indicating a 13% growth.
Sales from Lagevrio alone contributed to $436m.
In Q3 2022, sales from Gardasil/Gardasil 9 were reported to be $2.3bn, a growth of 15% from Q3 2021.
Increased sales of Keytruda, which grew by 20% to $5.4bn in Q3 2022, drove growth in oncology.
The company noted that the Covid-19 pandemic adversely impacted Q3 last year’s sales by nearly $350m, which favourably affected the growth rate in Q3 this year.
For the quarter ending on 30 September 2022, GAAP-based EPS from continuing operations was $1.28, indicating a 29% decline from $1.8 in the same quarter last year.
Non-GAAP EPS for Q3 2022 was recorded at $1.85, a growth of 4% from $1.78 in the last year.
Merck CEO and president Robert Davis said: “We continue to execute on our strategy, invest in leading-edge science and drive innovation as our colleagues deliver meaningful value for patients, which in turn provides value for our shareholders.
“Our third quarter results demonstrate exceptional revenue and underlying earnings growth and sustained performance across our key growth drivers.”
Anticipating a 20% to 21% rise in sales, the company has updated the full-year 2022 financial outlook and now expects worldwide sales between $58.5bn and $59bn.
The full-year 2022 GAAP EPS was reduced to a range of $5.68-$5.73, while non-GAAP EPS was raised to a range of $7.32-$7.37.
In September, Japan’s Ministry of Health, Labour and Welfare granted four new approvals for the company’s Keytruda to treat various types of cancers.